| First Author | Schreiber A | Year | 2012 |
| Journal | J Am Soc Nephrol | Volume | 23 |
| Issue | 3 | Pages | 470-82 |
| PubMed ID | 22241891 | Mgi Jnum | J:264172 |
| Mgi Id | MGI:6195459 | Doi | 10.1681/ASN.2010080892 |
| Citation | Schreiber A, et al. (2012) Neutrophil serine proteases promote IL-1beta generation and injury in necrotizing crescentic glomerulonephritis. J Am Soc Nephrol 23(3):470-82 |
| abstractText | The pathogenesis of anti-neutrophil cytoplasmic antibody (ANCA)-associated necrotizing crescentic GN (NCGN) is incompletely understood. Dipeptidyl peptidase I (DPPI) is a cysteine protease required for the activation of neutrophil serine proteases (NSPs) cathepsin G, neutrophil elastase, and proteinase 3, which are enzymes that modulate inflammation. We used a mouse model of anti-myeloperoxidase (MPO) antibody-induced NCGN to determine whether active NSPs contribute to its pathogenesis. MPO-deficient animals immunized with murine MPO, irradiated, and transplanted with wild-type bone marrow developed NCGN. In contrast, transplantation with bone marrow that lacked DPPI or lacked both neutrophil elastase and proteinase 3 protected mice from NCGN induced by anti-MPO antibody. The kidneys of mice reconstituted with DPPI-deficient bone marrow generated significantly less IL-1beta than did those of mice reconstituted with wild-type bone marrow; similarly, in vitro, DPPI-deficient monocytes produced significantly less IL-1beta in response to anti-MPO antibody than did wild-type monocytes. This reduction in IL-1beta was NSP dependent; exogenous addition of PR3 restored IL-beta production in DPPI-deficient monocytes. Last, the IL-1 receptor antagonist anakinra protected animals against anti-MPO antibody-induced NCGN (16.7%+/-6.0% versus 2.4%+/-1.7% crescents), suggesting that IL-1beta is a critical inflammatory mediator in this model. These data suggest that the development of anti-MPO antibody-induced NCGN requires NSP-dependent IL-1beta generation and that these processes may provide therapeutic targets for ANCA-mediated diseases in humans. |
